NT5E

Across TCGA pan-cancer cohorts, NT5E Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NT5E data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher NT5E Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NT5E expression acts as an unfavorable survival marker.

OV, SKCM, and SCLC are the cancer types where NT5E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.209	0.541	.020	18	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	8	view →
SCLC	DFS	Median	All	0.233	0.630	.040	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	II,III,IV	0.053	0.427	.003	6	view →
COAD	OS	Median	All	0.214	0.675	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NT5E–OV (DFS)

Open the OV breakdown →